CVR - Coronavirus Vaccines R&D Roadmap

Milestone
1.2.e

Virus stock panel

In progress
High priority

Generate at least one initial panel of virus stocks featuring different coronaviruses and diverse cell lines that are readily susceptible to various coronaviruses, and make the panel accessible to researchers working on coronavirus vaccine R&D.

Progress Highlights

BEI Resources has different coronavirus isolates and cell lines available for researchers, and similar products are available commercially, but there does not seem to be a single panel composed of multiple viruses or cell lines readily available for order online.

The WHO BioHub was established in 2021 to offer a reliable, safe, and transparent mechanism for WHO Member States to voluntarily share novel biological materials for SARS-CoV-2; in October 2025, the first MERS-CoV isolate (MERS-CoV/HK-HKU/HKU270/2025) was added to the BioHub

Letko 2020 developed methods for quick, functional assessment of cell entry and receptor usage by different coronaviruses which could potentially be used to create a panel.